ELVN Enliven Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ELVN

Price (delayed)

$22.65

Market cap

$936.52M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.01

Enterprise value

$836.33M

Highlights
Enliven Therapeutics's EPS has surged by 83% YoY and by 56% QoQ
The company's quick ratio has shrunk by 55% QoQ but it rose by 26% YoY
The company's net income has shrunk by 90% YoY and by 16% QoQ
ELVN's equity is down by 6% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of ELVN
Market
Shares outstanding
41.35M
Market cap
$936.52M
Enterprise value
$836.33M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.8
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$71.58M
EBITDA
-$70.98M
Free cash flow
-$61.42M
Per share
EPS
-$2.01
Free cash flow per share
-$1.73
Book value per share
$5.97
Revenue per share
$0
TBVPS
$7.65
Balance sheet
Total assets
$271.87M
Total liabilities
$25.96M
Debt
$0
Equity
$245.91M
Working capital
$240.26M
Liquidity
Debt to equity
0
Current ratio
10.28
Quick ratio
9.78
Net debt/EBITDA
1.41
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-25.2%
Return on equity
-26.6%
Return on invested capital
-58.8%
Return on capital employed
-29.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ELVN stock price

How has the Enliven Therapeutics stock price performed over time
Intraday
7.91%
1 week
31.84%
1 month
21.84%
1 year
14.68%
YTD
63.66%
QTD
28.77%

Financial performance

How have Enliven Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$83.53M
Net income
-$71.58M
Gross margin
N/A
Net margin
N/A
Enliven Therapeutics's operating income has shrunk by 115% YoY and by 18% QoQ
The company's net income has shrunk by 90% YoY and by 16% QoQ

Growth

What is Enliven Therapeutics's growth rate over time

Valuation

What is Enliven Therapeutics stock price valuation
P/E
N/A
P/B
3.8
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Enliven Therapeutics's EPS has surged by 83% YoY and by 56% QoQ
ELVN's P/B is 90% above its last 4 quarters average of 2.0
ELVN's equity is down by 6% QoQ

Efficiency

How efficient is Enliven Therapeutics business performance
ELVN's return on invested capital has surged by 86% year-on-year and by 19% since the previous quarter
Enliven Therapeutics's ROA has soared by 51% YoY and by 3.1% from the previous quarter
The return on equity is up by 19% since the previous quarter

Dividends

What is ELVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELVN.

Financial health

How did Enliven Therapeutics financials performed over time
ELVN's total liabilities has soared by 150% year-on-year and by 111% since the previous quarter
The company's quick ratio has shrunk by 55% QoQ but it rose by 26% YoY
The debt is 100% less than the equity
ELVN's equity is down by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.